The COVID-19 pandemic has changed the way we work and live virtually overnight, making it increasingly difficult to stay on top of the deal-making landscape, track competitive clinical development activities and find new opportunities for expansion influenced by the shifting COVID-19 landscape. But working from home doesn’t mean your pipeline analysis should be compromised.
COVID-19 is sparking all kinds of innovation – from testing and treatments to drug repurposing and vaccines. Local health authorities are releasing new guidance at breakneck speed, making it increasingly difficult to stay on top of it all.
From monitoring protocol and patient eligibility criteria changes to evaluating the feasibility of alternate sites and tracking peers’ activities to inform your own strategy, COVID-19 is disrupting clinical development and making it more challenging than ever to understand the trial landscape.
As scientists develop vaccines and treatments to meet the urgent needs of those affected by COVID-19, it’s becoming increasingly difficult to cut through the noise and keep track of all the new therapies, vaccines, targets and experimental results to inform your research.